Drugs / LAZUCIRNON
LAZUCIRNON
also known as
BI144807 · AKST4290 · ALK4290 · AKST-4290 DIHYDROCHLORIDE · ALK-429 · ALK-4290 DIHYDROCHLORIDE · BI-144807 2HCL · BI-144807 DIHYDROCHLORIDE · +3 more
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01897597 | Jul → Sep 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01707940 | Oct → Dec 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01651598 | Jul 2012 → Jan 2013 | asthma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01480648 | Nov 2011 → Feb 2012 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05038020 | Aug → Dec 2021 | diabetic retinopathy | Alkahest, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04499235 | Jan 2020 → Mar 2021 | bullous pemphigoid | Alkahest, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04331730 | Jan 2020 → Aug 2021 | wet macular degeneration | Alkahest, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04369430 | Jan 2020 → Feb 2021 | Parkinson disease | Alkahest, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03558074 | Apr → Nov 2018 | wet macular degeneration | Alkahest, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03558061 | Apr → Nov 2018 | wet macular degeneration | Alkahest, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02121522 | Jun 2014 → Mar 2015 | wet macular degeneration | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAZUCIRNON | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670800 ↗ |
| Known as | AKST-4290 DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670800 ↗ |
| Known as | AKST4290 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04331730 ↗ |
| Known as | ALK-429 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670800 ↗ |
| Known as | ALK-4290 DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670800 ↗ |
| Known as | ALK4290 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03558074 ↗ |
| Known as | BI-144807 2HCL | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670800 ↗ |
| Known as | BI-144807 DIHYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670800 ↗ |
| Known as | BI144807 | “BI144807 oral solution, intermediate dose” NCT01707940 ↗ |
| Known as | BI144807 CL2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670800 ↗ |
| Known as | Lazucirnon dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670800 ↗ |
| Known as | LAZUCIRNON HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3670800 ↗ |
| Modality | Small molecule | — CHEMBL3670800 ↗ |
| Route | Oral | “Single Rising Oral Doses” NCT01480648 ↗ |